Table of Contents
Clinical trial overview
The trial NCT05501717 studied adults with antibody-mediated rejection after kidney transplantation.[1] It was a Phase 2, interventional study and was listed as authorised.[1]
The study compared “RNA, (AM-SP-UM-CM-AM-AM-CM-UM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)A-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)C-UM-GM-UM-AM-AM-UM-AM-AM-AM-GM-CM-AM-GM-CM-CM-GM-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-[2′-O-[[2-[2-[[5-[[2-(ACETYLAMINO)-2-DEOXY-BETA-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]ETHOXY]ETHOXY]METHYL]]A-GM-GM-CM-UM-GM-CM), COMPLEX WITH RNA ([4′-DE(HYDROXYMETHYL)-4′-[(HYDROXYMETHOXYPHOSPHINYL)METHOXY]]UM-SP-(2′-DEOXY-2′-FLUORO)U-SP-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-(2′-DEOXY-2′-FLUORO)U-UM-(2′-DEOXY-2′-FLUORO)A-CM-AM-(2′-DEOXY-2′-FLUORO)G-GM-UM-GM-(2′-DEOXY-2′-FLUORO)A-GM-UM-UM-GM-AM-UM-SP-GM-SP-GM)” with a vialed saline placebo.[1]
Who was studied
The target population was adults with either active or chronic active antibody-mediated rejection after kidney transplantation.[1] The study enrollment was 50 participants.[1]
This means the trial focused on people whose transplanted kidney was showing signs of rejection caused by antibodies, which are proteins made by the immune system.[1]
Study design and phase
This was an interventional trial, so participants received a study treatment or placebo rather than only being observed.[1] The trial phase was Phase 2, which usually means the researchers were looking more closely at whether the treatment works and also continuing safety checks.[1]
The study’s brief summary says the goal was to compare the treatment against placebo for biopsy-proven histologic resolution in participants with active or chronic active AMR at Week 52.[1]
Main endpoint
The primary outcome was biopsy-proven histologic resolution at Week 52.[1] A biopsy is a small tissue sample, and histologic resolution means the kidney tissue looks improved or healed when seen under the microscope.[1]
This endpoint is important because it checks the kidney tissue directly, not just symptoms or lab results.[1] The Week 52 time point means the result was measured about one year after the study started.[1]
What the results mean
From the trial data provided, this study is designed to find out whether the treatment can help the transplanted kidney recover better than placebo in adults with antibody-mediated rejection.[1] The most important measure is whether the kidney biopsy shows resolution by Week 52.[1]
Because the source data only provides trial design details, this article does not report final results or long-term outcomes.[1]
